Davis Rea LTD. Purchases New Shares in Intuitive Surgical, Inc. $ISRG

Davis Rea LTD. acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 15,474 shares of the medical equipment provider’s stock, valued at approximately $6,920,000. Intuitive Surgical makes up 1.7% of Davis Rea LTD.’s holdings, making the stock its 19th biggest position.

A number of other hedge funds have also bought and sold shares of ISRG. Norges Bank bought a new stake in shares of Intuitive Surgical in the 2nd quarter worth about $2,569,260,000. Vanguard Group Inc. lifted its stake in Intuitive Surgical by 2.1% in the second quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after purchasing an additional 670,302 shares during the last quarter. Jennison Associates LLC lifted its stake in Intuitive Surgical by 20.4% in the second quarter. Jennison Associates LLC now owns 3,122,390 shares of the medical equipment provider’s stock worth $1,696,738,000 after purchasing an additional 528,359 shares during the last quarter. Bessemer Group Inc. boosted its position in shares of Intuitive Surgical by 89.3% during the second quarter. Bessemer Group Inc. now owns 788,328 shares of the medical equipment provider’s stock valued at $428,386,000 after buying an additional 371,806 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in shares of Intuitive Surgical by 25.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,582,280 shares of the medical equipment provider’s stock valued at $859,827,000 after buying an additional 317,324 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $541.34 on Friday. The firm has a 50-day simple moving average of $566.82 and a 200-day simple moving average of $512.30. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The firm has a market cap of $194.06 billion, a P/E ratio of 71.61, a P/E/G ratio of 4.44 and a beta of 1.67.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.41. The company had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.41 billion. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. Intuitive Surgical’s revenue was up 22.9% compared to the same quarter last year. During the same period last year, the company posted $1.84 earnings per share. On average, research analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ISRG shares. BTIG Research reissued a “buy” rating and set a $616.00 price target (up from $589.00) on shares of Intuitive Surgical in a research note on Wednesday, January 7th. Raymond James Financial set a $603.00 target price on Intuitive Surgical and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Wells Fargo & Company boosted their target price on shares of Intuitive Surgical from $600.00 to $654.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Weiss Ratings restated a “hold (c+)” rating on shares of Intuitive Surgical in a report on Monday, December 29th. Finally, Argus lifted their price objective on shares of Intuitive Surgical from $600.00 to $630.00 in a report on Monday, October 27th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $622.17.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Preliminary Q4 and full‑year 2025 results beat expectations: procedure volume, system placements and revenue all grew, and management raised full‑year revenue guidance vs prior consensus—evidence of demand strength. Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Industry analysts reiterated buy/supportive views: Bernstein kept a Buy rating and William Blair reiterated bullish sentiment citing DV5 adoption and pipeline, which supports longer‑term growth expectations. Bernstein Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
• Positive Sentiment: Company commentary and industry coverage note da Vinci systems “exceeded expectations” in procedures and placements, underlining the platform’s commercial traction. Intuitive says daVinci systems ‘exceeded expectations,’ it wants more
• Neutral Sentiment: IS‑001 Phase 3 update (imaging‑driven safety product) is in progress — relevant for the pipeline but uncertain timing/impact on revenue; watch trial readouts. IS-001 Phase 3 Update
• Neutral Sentiment: da Vinci 5 international rollout is expanding but faces pricing, budget and reimbursement hurdles overseas — a mixed catalyst: growth potential but adoption risk outside the U.S. da Vinci 5 Expands Globally
• Negative Sentiment: Management set a softer 2026 outlook and lowered its expected da Vinci growth cadence for the year, which overshadowed the Q4 beat and prompted the pullback as investors re‑price growth expectations. Intuitive Surgical Sets Softer 2026 Outlook
• Negative Sentiment: Market reaction focused on a missed/tepid 2026 da Vinci growth projection despite solid quarterly results — traders viewed this as evidence of near‑term deceleration. da Vinci Growth Projection Misses Expectations
• Negative Sentiment: Commentary across outlets: “shares fell despite beating Q4” highlights investor sensitivity to forward guidance and valuation (high PE multiple); this sentiment amplified the decline. Why Intuitive Surgical Stock Is Falling Today

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 7,562 shares of Intuitive Surgical stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $548.43, for a total value of $4,147,227.66. Following the transaction, the executive vice president owned 353 shares in the company, valued at $193,595.79. The trade was a 95.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary S. Guthart sold 28,800 shares of the business’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $547.56, for a total transaction of $15,769,728.00. Following the completion of the transaction, the insider owned 27,027 shares of the company’s stock, valued at $14,798,904.12. This represents a 51.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 114,007 shares of company stock worth $63,533,844. Insiders own 0.70% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.